539 related articles for article (PubMed ID: 19356802)
1. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.
Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R
Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802
[TBL] [Abstract][Full Text] [Related]
2. Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis.
Khan AA; Babu JP; Gupta G; Rao DN
Vaccine; 2008 Jan; 26(3):316-32. PubMed ID: 18096277
[TBL] [Abstract][Full Text] [Related]
3. Passive vaccination with a human monoclonal antibody: generation of antibodies and studies for efficacy in Bacillus anthracis infections.
vor dem Esche U; Huber M; Zgaga-Griesz A; Grunow R; Beyer W; Hahn U; Bessler WG
Immunobiology; 2011 Jul; 216(7):847-53. PubMed ID: 21397977
[TBL] [Abstract][Full Text] [Related]
4. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope.
Zhang J; Xu J; Li G; Dong D; Song X; Guo Q; Zhao J; Fu L; Chen W
Biochem Biophys Res Commun; 2006 Mar; 341(4):1164-71. PubMed ID: 16460675
[TBL] [Abstract][Full Text] [Related]
5. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.
Yin Y; Zhang S; Cai C; Zhang J; Dong D; Guo Q; Fu L; Xu J; Chen W
Immunobiology; 2014 Feb; 219(2):97-103. PubMed ID: 24054942
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal antibodies to B.anthracis protective antigen are capable to neutralize and to enhance the anthrax lethal toxin action in vitro].
Belova EV; Dubileĭ SA; Kravchenko TB; Kolesnikov AV; Zakharova MIu; Shemiakin IG
Mol Gen Mikrobiol Virusol; 2004; (3):21-6. PubMed ID: 15354937
[TBL] [Abstract][Full Text] [Related]
7. Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.
Dumas EK; Nguyen ML; Cox PM; Rodgers H; Peterson JL; James JA; Farris AD
Vaccine; 2013 Apr; 31(14):1856-63. PubMed ID: 23415781
[TBL] [Abstract][Full Text] [Related]
8. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
9. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
[TBL] [Abstract][Full Text] [Related]
10. [Toxin-neutralizing monoclonal antibodies to the different domains of anthrax protective antigen].
Xu JJ; Zhang J; Liu SL; Lv TJ; Chen W; Li GL; Ge M; Guo Q
Wei Sheng Wu Xue Bao; 2005 Dec; 45(6):947-51. PubMed ID: 16496709
[TBL] [Abstract][Full Text] [Related]
11. Generation of mouse polyclonal and human monoclonal antibodies against Bacillus anthracis toxin.
Huber M; Vor Dem Esche U; Grunow R; Bessler WG
Drugs Exp Clin Res; 2005; 31(2):35-43. PubMed ID: 15929604
[TBL] [Abstract][Full Text] [Related]
12. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
13. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.
Tripathi V; Chitralekha KT; Bakshi AR; Tomar D; Deshmukh RA; Baig MA; Rao DN
Vaccine; 2006 Apr; 24(16):3279-89. PubMed ID: 16476510
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel multiepitope chimeric vaccine against anthrax.
Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
[TBL] [Abstract][Full Text] [Related]
15. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses.
Midha S; Bhatnagar R
Eur J Immunol; 2009 Jan; 39(1):159-77. PubMed ID: 19130551
[TBL] [Abstract][Full Text] [Related]
16. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.
Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL
Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272
[TBL] [Abstract][Full Text] [Related]
17. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen.
Steiniger SC; Altobell LJ; Zhou B; Janda KD
Mol Immunol; 2007 Apr; 44(10):2749-55. PubMed ID: 17210180
[TBL] [Abstract][Full Text] [Related]
18. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination.
Hahn UK; Alex M; Czerny CP; Böhm R; Beyer W
Int J Med Microbiol; 2004 Jul; 294(1):35-44. PubMed ID: 15293452
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.
Abboud N; Casadevall A
Clin Vaccine Immunol; 2008 Jul; 15(7):1115-23. PubMed ID: 18480236
[TBL] [Abstract][Full Text] [Related]
20. Design and evaluation of a multi-epitope peptide against Japanese encephalitis virus infection in BALB/c mice.
Wei JC; Huang YZ; Zhong DK; Kang L; Ishag H; Mao X; Cao RB; Zhou B; Chen PY
Biochem Biophys Res Commun; 2010 Jun; 396(4):787-92. PubMed ID: 20457131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
